No. |
薬物名(臨床試験情報から抽出) |
DrugBank |
KEGG DRUG * |
KEGG GENES * |
KEGG PATHWAY |
指定難病告示番号 * |
1 |
(18)f-fdg |
- |
- |
- |
- |
1件: 85 |
2 |
534-1508 |
- |
- |
- |
- |
1件: 85 |
3 |
68ga-bmv101 |
- |
- |
- |
- |
1件: 85 |
4 |
[18f]-fba-a20fmdv2 |
- |
- |
- |
- |
1件: 85 |
5 |
[18f]fp-r01-mg-f2 |
- |
- |
- |
- |
1件: 85 |
6 |
[68ga]cbp8 |
- |
- |
- |
- |
1件: 85 |
7 |
Acetate |
Acetate |
- |
- |
- |
40件: 1, 2, 6, 10, 13, 35, 40, 46, 49, 51, 60, 64, 70, 71, 73, 75, 76, 78, 81, 83, 85, 86, 88, 90, 96, 97, 113, 145, 156, 162, 171, 206, 222, 224, 225, 235, 265, 288, 298, 299 |
8 |
Acetylcysteine |
Acetylcysteine |
D00221 |
- |
- |
14件: 6, 13, 19, 20, 49, 51, 58, 85, 94, 111, 164, 233, 298, 299 |
9 |
Act-064992 |
- |
- |
- |
- |
4件: 85, 86, 88, 210 |
10 |
Act-064992 (macitentan) |
Macitentan |
D10135 |
2件: EDNRA, EDNRB |
9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
1件: 85 |
11 |
Adult human mesenchymal stem cells |
Remestemcel-l |
D09719 |
- |
- |
2件: 85, 96 |
12 |
Aerosol interferon-gamma |
- |
- |
- |
- |
1件: 85 |
13 |
Alemtuzumab |
Alemtuzumab |
D02802 |
- |
- |
13件: 13, 15, 19, 20, 46, 51, 60, 63, 65, 85, 96, 164, 284 |
14 |
Allogeneic adult human mesenchymal stem cells (hmscs) |
Remestemcel-l |
D09719 |
- |
- |
1件: 85 |
15 |
Ambrisentan |
Ambrisentan |
D07077 |
1件: EDNRA |
7件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Pathways in cancer, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
6件: 51, 84, 85, 86, 88, 211 |
16 |
Antimicrobial therapy: co-trimoxazole or doxycycline |
Doxycycline |
D00307, D02129, D03903, D03904, D07876 |
- |
- |
1件: 85 |
17 |
Art-123 |
- |
- |
- |
- |
1件: 85 |
18 |
Atezolizumab |
Atezolizumab |
D10773 |
1件: CD274 |
2件: Cell adhesion molecules (CAMs), PD-L1 expression and PD-1 checkpoint pathway in cancer |
1件: 85 |
19 |
Autoantibody reductive therapy |
- |
- |
- |
- |
1件: 85 |
20 |
Autologous adipose derived mscs (admscs) |
- |
- |
- |
- |
1件: 85 |
21 |
Autologous mesenchymal stem cells derived from bone marrow |
- |
- |
- |
- |
1件: 85 |
22 |
Autologous stromal vascular fraction (svf) |
- |
- |
- |
- |
1件: 85 |
23 |
Aviptadil |
Aviptadil |
- |
- |
- |
4件: 49, 51, 85, 86 |
24 |
Aviptadil, 66 microgram/ml |
Aviptadil |
- |
- |
- |
1件: 85 |
25 |
Azapred |
- |
- |
- |
- |
1件: 85 |
26 |
Azathioprine |
Azathioprine |
D00238, D03033 |
- |
- |
18件: 11, 13, 19, 35, 42, 43, 44, 45, 46, 49, 65, 66, 85, 94, 95, 96, 97, 162 |
27 |
Azathioprine/prednisone |
Azathioprine |
D00238, D03033 |
- |
- |
1件: 85 |
28 |
Azithromycin |
Azithromycin |
D02134, D06390, D07486 |
- |
- |
6件: 13, 84, 85, 96, 228, 299 |
29 |
Bardoxolone |
Bardoxolone |
D09584 |
- |
- |
7件: 66, 67, 84, 85, 86, 218, 222 |
30 |
Bardoxolone methyl |
Bardoxolone methyl |
D09585 |
- |
- |
7件: 66, 67, 84, 85, 86, 218, 222 |
31 |
Bbt-877, multiple doses |
- |
- |
- |
- |
1件: 85 |
32 |
Bbt-877, single dose |
- |
- |
- |
- |
1件: 85 |
33 |
Bevacizumab |
Bevacizumab |
D06409 |
1件: VEGFA |
21件: AGE-RAGE signaling pathway in diabetic complications, Bladder cancer, EGFR tyrosine kinase inhibitor resistance, Fluid shear stress and atherosclerosis, Focal adhesion, HIF-1 signaling pathway, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, MAPK signaling pathway, MicroRNAs in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Relaxin signaling pathway, Renal cell carcinoma, Rheumatoid arthritis, VEGF signaling pathway |
9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 |
34 |
Bg00011 |
- |
- |
- |
- |
1件: 85 |
35 |
Bi 1015550 |
- |
- |
- |
- |
1件: 85 |
36 |
Bibf 1120 |
- |
- |
- |
- |
2件: 51, 85 |
37 |
Blood sample collection |
- |
- |
- |
- |
1件: 85 |
38 |
Bms-986020 |
- |
- |
- |
- |
2件: 51, 85 |
39 |
Bms-986278 |
- |
- |
- |
- |
1件: 85 |
40 |
Bone marrow mesenchymal stem cells |
- |
- |
- |
- |
1件: 85 |
41 |
Bosentan |
Bosentan |
D01227, D07538 |
2件: EDNRA, EDNRB |
9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
9件: 13, 41, 47, 51, 84, 85, 86, 88, 210 |
42 |
Carbon |
Activated charcoal |
D03251 |
- |
- |
7件: 6, 46, 85, 86, 96, 97, 298 |
43 |
Carbon monoxide |
Carbon monoxide |
D09706 |
- |
- |
3件: 85, 86, 298 |
44 |
Carboplatin |
Carboplatin |
D01363 |
- |
- |
4件: 28, 34, 60, 85 |
45 |
Cbdca |
Carboplatin |
D01363 |
- |
- |
1件: 85 |
46 |
Cc-90001 |
- |
- |
- |
- |
1件: 85 |
47 |
Cc-930 |
- |
- |
- |
- |
1件: 85 |
48 |
Cd3/cd19 negative hematopoietic stem cells |
- |
- |
- |
- |
1件: 85 |
49 |
Cnto 888 1 mg/kg |
- |
- |
- |
- |
1件: 85 |
50 |
Cnto 888 15 mg/kg |
- |
- |
- |
- |
1件: 85 |
51 |
Cnto 888 5 mg/kg |
- |
- |
- |
- |
1件: 85 |
52 |
Cnto888 |
- |
- |
- |
- |
1件: 85 |
53 |
Co-trimoxazole |
- |
- |
- |
- |
1件: 85 |
54 |
Combined plasma exchange (pex), rituximab, and corticosteroids |
Rituximab |
D02994 |
1件: MS4A1 |
1件: Hematopoietic cell lineage |
1件: 85 |
55 |
Corticosteroid (prednisolone) |
Prednisolone |
D00472, D00980, D00981, D00982, D01239, D01998, D02156, D03301 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
1件: 85 |
56 |
Cotrimoxazole |
- |
- |
- |
- |
2件: 85, 97 |
57 |
Cromoglycate |
Cromoglicic acid |
D00526, D07753 |
- |
- |
1件: 85 |
58 |
Cromolyn |
Cromoglicic acid |
D00526, D07753 |
- |
- |
2件: 85, 98 |
59 |
Cromolyn sodium |
Cromoglicic acid |
D00526, D07753 |
- |
- |
1件: 85 |
60 |
Cyclophosphamide |
Cyclophosphamide |
D00287, D07760 |
- |
- |
43件: 13, 14, 16, 19, 20, 26, 28, 35, 36, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 52, 56, 60, 61, 62, 65, 66, 84, 85, 93, 96, 162, 164, 172, 222, 224, 265, 274, 283, 284, 285, 288, 326, 331 |
61 |
Cysteine |
L-cysteine |
D00026, D02326 |
- |
- |
9件: 6, 13, 19, 84, 85, 88, 90, 254, 296 |
62 |
Dabigatran |
Dabigatran |
D09707 |
1件: F2 |
7件: Complement and coagulation cascades, Neuroactive ligand-receptor interaction, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Platelet activation, Regulation of actin cytoskeleton |
2件: 85, 91 |
63 |
Dasatinib |
Dasatinib |
D03658, D06414 |
8件: ABL1, EPHA2, FYN, KIT, LCK, PDGFRB, SRC, YES1 |
73件: Acute myeloid leukemia, Adherens junction, Axon guidance, Bacterial invasion of epithelial cells, Bladder cancer, Breast cancer, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Chemokine signaling pathway, Choline metabolism in cancer, Cholinergic synapse, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endocytosis, Epithelial cell signaling in Helicobacter pylori infection, ErbB signaling pathway, Estrogen signaling pathway, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Focal adhesion, GABAergic synapse, Gap junction, Glioma, GnRH signaling pathway, Hematopoietic cell lineage, Hepatitis B, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Inflammatory mediator regulation of TRP channels, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Mitophagy - animal, NF-kappa B signaling pathway, Natural killer cell mediated cytotoxicity, Neurotrophin signaling pathway, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Platelet activation, Primary immunodeficiency, Prion diseases, Prolactin signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Relaxin signaling pathway, Shigellosis, Sphingolipid signaling pathway, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Thyroid hormone signaling pathway, Tight junction, Tuberculosis, VEGF signaling pathway, Viral carcinogenesis, Viral myocarditis, Yersinia infection |
1件: 85 |
64 |
Dasatinib + quercetin |
Dasatinib, Quercetin |
D03658, D06414 |
8件: ABL1, EPHA2, FYN, KIT, LCK, PDGFRB, SRC, YES1 |
73件: Acute myeloid leukemia, Adherens junction, Axon guidance, Bacterial invasion of epithelial cells, Bladder cancer, Breast cancer, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Chemokine signaling pathway, Choline metabolism in cancer, Cholinergic synapse, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endocytosis, Epithelial cell signaling in Helicobacter pylori infection, ErbB signaling pathway, Estrogen signaling pathway, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Focal adhesion, GABAergic synapse, Gap junction, Glioma, GnRH signaling pathway, Hematopoietic cell lineage, Hepatitis B, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Inflammatory mediator regulation of TRP channels, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Mitophagy - animal, NF-kappa B signaling pathway, Natural killer cell mediated cytotoxicity, Neurotrophin signaling pathway, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Platelet activation, Primary immunodeficiency, Prion diseases, Prolactin signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Relaxin signaling pathway, Shigellosis, Sphingolipid signaling pathway, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Thyroid hormone signaling pathway, Tight junction, Tuberculosis, VEGF signaling pathway, Viral carcinogenesis, Viral myocarditis, Yersinia infection |
1件: 85 |
65 |
Disodium cromoglycate (dscg) |
Cromoglicic acid |
D00526, D07753 |
- |
- |
1件: 85 |
66 |
Disodium cromoglycate [cromolyn sodium] |
Cromoglicic acid |
D00526, D07753 |
- |
- |
1件: 85 |
67 |
Doxycycline |
Doxycycline |
D00307, D02129, D03903, D03904, D07876 |
- |
- |
15件: 13, 23, 28, 46, 84, 85, 89, 96, 97, 158, 162, 167, 227, 280, 299 |
68 |
Egcg |
Epigallocatechin gallate |
- |
- |
- |
8件: 6, 13, 17, 28, 85, 113, 206, 299 |
69 |
Endobronchial infusion of adult mesenchymal stem cells |
- |
- |
- |
- |
1件: 85 |
70 |
Epigallocatechin |
Epigallocatechin |
- |
- |
- |
4件: 13, 28, 85, 113 |
71 |
Epigallocatechin-3-gallate (egcg) |
Epigallocatechin |
- |
- |
- |
2件: 28, 85 |
72 |
Esbriet |
Pirfenidone |
D01583 |
6件: CCL2, IL10, IL1A, IL1B, IL6, TNF |
80件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, Autoimmune thyroid disease, C-type lectin receptor signaling pathway, Cellular senescence, Chagas disease (American trypanosomiasis), Chemokine signaling pathway, Cytokine-cytokine receptor interaction, Cytosolic DNA-sensing pathway, Dilated cardiomyopathy (DCM), EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, FoxO signaling pathway, Graft-versus-host disease, HIF-1 signaling pathway, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Inflammatory mediator regulation of TRP channels, Influenza A, Insulin resistance, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, Measles, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Pertussis, Prion diseases, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Staphylococcus aureus infection, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Transcriptional misregulation in cancer, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
3件: 51, 85, 228 |
73 |
Esbriet® (pirfenidon) |
Pirfenidone |
D01583 |
6件: CCL2, IL10, IL1A, IL1B, IL6, TNF |
80件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, Autoimmune thyroid disease, C-type lectin receptor signaling pathway, Cellular senescence, Chagas disease (American trypanosomiasis), Chemokine signaling pathway, Cytokine-cytokine receptor interaction, Cytosolic DNA-sensing pathway, Dilated cardiomyopathy (DCM), EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, FoxO signaling pathway, Graft-versus-host disease, HIF-1 signaling pathway, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Inflammatory mediator regulation of TRP channels, Influenza A, Insulin resistance, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, Measles, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Pertussis, Prion diseases, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Staphylococcus aureus infection, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Transcriptional misregulation in cancer, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
1件: 85 |
74 |
Etanercept |
Etanercept |
D00742 |
2件: LTA, TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
14件: 15, 35, 38, 39, 46, 50, 53, 56, 60, 85, 228, 271, 285, 298 |
75 |
Etoposide |
Etoposide |
D00125, D04107 |
2件: TOP2A, TOP2B |
1件: Platinum drug resistance |
11件: 11, 13, 14, 26, 28, 34, 60, 65, 85, 164, 331 |
76 |
Ez-2053 |
- |
- |
- |
- |
2件: 85, 299 |
77 |
Ez-2053 5mg/kg |
- |
- |
- |
- |
2件: 85, 299 |
78 |
Fentanyl |
Fentanyl |
D00320, D01399 |
1件: OPRM1 |
3件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction |
5件: 46, 70, 85, 215, 231 |
79 |
Fentanyl citrate |
Fentanyl |
D00320, D01399 |
1件: OPRM1 |
3件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction |
1件: 85 |
80 |
Fg-3019 |
- |
- |
- |
- |
2件: 85, 222 |
81 |
Fg-3019 10mg/ml in 10 ml vials |
- |
- |
- |
- |
1件: 85 |
82 |
Fludarabine |
Fludarabine |
D01907, D07966 |
1件: RRM1 |
5件: Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism |
17件: 13, 28, 36, 46, 49, 51, 60, 61, 62, 65, 85, 96, 164, 283, 284, 285, 326 |
83 |
Fluimucil® 600 mg effervescent tablets |
- |
- |
- |
- |
1件: 85 |
84 |
Fluorine (18f) fludeoxyglucose |
- |
- |
- |
- |
2件: 84, 85 |
85 |
Fostair |
- |
- |
- |
- |
1件: 85 |
86 |
G-csf |
Filgrastim |
D03235 |
1件: CSF3R |
5件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer |
12件: 6, 13, 16, 49, 51, 60, 65, 85, 96, 284, 285, 331 |
87 |
G321605 |
- |
- |
- |
- |
3件: 85, 96, 97 |
88 |
G451990 |
- |
- |
- |
- |
1件: 85 |
89 |
Gallium68-dota-noc |
- |
- |
- |
- |
1件: 85 |
90 |
Gbt440 |
- |
- |
- |
- |
1件: 85 |
91 |
Gc1008 |
Fresolimumab |
D09620 |
3件: TGFB1, TGFB2, TGFB3 |
34件: AGE-RAGE signaling pathway in diabetic complications, Amoebiasis, Cell cycle, Cellular senescence, Chagas disease (American trypanosomiasis), Chronic myeloid leukemia, Colorectal cancer, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), FoxO signaling pathway, Gastric cancer, Hepatitis B, Hepatocellular carcinoma, Hippo signaling pathway, Human T-cell leukemia virus 1 infection, Hypertrophic cardiomyopathy (HCM), Inflammatory bowel disease (IBD), Intestinal immune network for IgA production, Leishmaniasis, MAPK signaling pathway, Malaria, MicroRNAs in cancer, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pancreatic cancer, Pathways in cancer, Proteoglycans in cancer, Relaxin signaling pathway, Renal cell carcinoma, Rheumatoid arthritis, TGF-beta signaling pathway, Th17 cell differentiation, Toxoplasmosis, Tuberculosis |
2件: 85, 222 |
92 |
Gefapixant |
Gefapixant |
D11349 |
1件: P2RX3 |
3件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Taste transduction |
2件: 85, 226 |
93 |
Gefapixant first, |
Gefapixant |
D11349 |
1件: P2RX3 |
3件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Taste transduction |
1件: 85 |
94 |
Gkt137831 |
- |
- |
- |
- |
2件: 85, 93 |
95 |
Glpg1205 |
Glpg1205 |
- |
- |
- |
3件: 85, 96, 97 |
96 |
Glpg1690 |
- |
- |
- |
- |
2件: 51, 85 |
97 |
Granulocyte colony stimulating factor |
Filgrastim |
D03235 |
1件: CSF3R |
5件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer |
3件: 2, 36, 85 |
98 |
Gs-6624 |
Simtuzumab |
- |
- |
- |
1件: 85 |
99 |
Gsk2126458 |
- |
- |
- |
- |
1件: 85 |
100 |
Gsk3008348 |
- |
- |
- |
- |
1件: 85 |
101 |
Gsk3008348 nebuliser solution |
- |
- |
- |
- |
1件: 85 |
102 |
Hec 68498 |
- |
- |
- |
- |
1件: 85 |
103 |
Hec585 |
- |
- |
- |
- |
1件: 85 |
104 |
High dose bibf 1120 twice daily |
- |
- |
- |
- |
1件: 85 |
105 |
Humanized anti-alpha v beta 6 mab |
- |
- |
- |
- |
1件: 85 |
106 |
Hydroxyurea |
Hydroxyurea |
D00341 |
1件: RRM2 |
6件: Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism, p53 signaling pathway |
8件: 3, 13, 19, 20, 65, 85, 86, 284 |
107 |
Hyperoxia |
- |
- |
- |
- |
1件: 85 |
108 |
Hyperpolarized 129 xenon gas comparing idiopathic pulmonary fibrosis (ipf) treatment |
Xenon |
D01901, D06339 |
- |
- |
1件: 85 |
109 |
Hyperpolarized 129-xenon gas |
Xenon |
D01901, D06339 |
- |
- |
1件: 85 |
110 |
Idl-2965 oral capsule |
- |
- |
- |
- |
1件: 85 |
111 |
Iloprost |
Iloprost |
D02721 |
1件: PTGIR |
3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
4件: 51, 84, 85, 86 |
112 |
Iloprost inhalation solution (ventavis) |
Iloprost |
D02721 |
1件: PTGIR |
3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
2件: 85, 86 |
113 |
Imatinib |
Imatinib |
D01441, D08066 |
3件: ABL1, KIT, PDGFRA |
32件: Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Shigellosis, Viral myocarditis |
11件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 89, 162 |
114 |
Imatinib mesylate (gleevec) |
Imatinib |
D01441, D08066 |
3件: ABL1, KIT, PDGFRA |
32件: Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Shigellosis, Viral myocarditis |
1件: 85 |
115 |
Immukin |
- |
- |
- |
- |
1件: 85 |
116 |
Inhaled carbon monoxide |
Carbon monoxide |
D09706 |
- |
- |
1件: 85 |
117 |
Inhaled nitric oxide |
Nitric oxide |
D00074 |
- |
- |
2件: 85, 86 |
118 |
Inhaled nitric oxide - 30 mcg/kg ibw/hr |
Nitric oxide |
D00074 |
- |
- |
1件: 85 |
119 |
Inhaled nitric oxide 5,10,15 mcg/kg ibw/hr |
Nitric oxide |
D00074 |
- |
- |
1件: 85 |
120 |
Inhaled nitric oxide 75 mcg/kg ibw/hr |
Nitric oxide |
D00074 |
- |
- |
2件: 85, 86 |
121 |
Inhaled td139 |
Td139 |
- |
- |
- |
1件: 85 |
122 |
Inomax 400ppm mol/mol inhalation gas |
Nitric oxide |
D00074 |
- |
- |
2件: 85, 299 |
123 |
Interferon alpha oral lozenge |
- |
- |
- |
- |
1件: 85 |
124 |
Interferon gamma-1b |
- |
- |
- |
- |
7件: 65, 85, 90, 228, 299, 301, 326 |
125 |
Interferon gamma-1b (actimmune) |
Interferon gamma-1b |
D00747 |
2件: IFNGR1, IFNGR2 |
19件: Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, HIF-1 signaling pathway, Herpes simplex virus 1 infection, Inflammatory bowel disease (IBD), Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways in cancer, Salmonella infection, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis |
1件: 85 |
126 |
Interferon-alpha lozenges |
- |
- |
- |
- |
1件: 85 |
127 |
Interferon-gamma 1b |
- |
- |
- |
- |
1件: 85 |
128 |
Intermediate dose bibf 1120 twice daily |
- |
- |
- |
- |
1件: 85 |
129 |
Intravenous immunoglobulin |
Immune globulin human |
- |
- |
- |
16件: 2, 11, 14, 17, 18, 35, 38, 39, 49, 51, 63, 65, 85, 164, 296, 309 |
130 |
Ivig |
Immune globulin human |
- |
- |
- |
12件: 11, 13, 14, 17, 18, 50, 51, 63, 65, 85, 164, 296 |
131 |
Iw001 |
- |
- |
- |
- |
1件: 85 |
132 |
Kd025 |
- |
- |
- |
- |
2件: 51, 85 |
133 |
L - antineoplastic and immunomodulating agents |
- |
- |
- |
- |
1件: 85 |
134 |
L01 - antineoplastic agents |
- |
- |
- |
- |
1件: 85 |
135 |
L01x - other antineoplastic agents |
- |
- |
- |
- |
1件: 85 |
136 |
L01xe - protein kinase inhibitors |
- |
- |
- |
- |
1件: 85 |
137 |
L01xe31 - nintedanib |
Nintedanib |
D10481 |
8件: FGFR1, FGFR2, FGFR3, FLT1, FLT4, KDR, PDGFRA, PDGFRB |
34件: Adherens junction, Bladder cancer, Breast cancer, Calcium signaling pathway, Central carbon metabolism in cancer, Choline metabolism in cancer, EGFR tyrosine kinase inhibitor resistance, Endocytosis, Fluid shear stress and atherosclerosis, Focal adhesion, Gap junction, Gastric cancer, Glioma, HIF-1 signaling pathway, Human cytomegalovirus infection, Human papillomavirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanoma, MicroRNAs in cancer, PI3K-Akt signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Rheumatoid arthritis, Signaling pathways regulating pluripotency of stem cells, Thermogenesis, Transcriptional misregulation in cancer, VEGF signaling pathway |
1件: 85 |
138 |
Lanreotide |
Lanreotide |
D04666 |
- |
- |
4件: 67, 73, 85, 298 |
139 |
Lanreotide acetate |
Lanreotide |
D04666 |
- |
- |
3件: 73, 85, 298 |
140 |
Lebrikizumab |
Lebrikizumab |
D09633 |
1件: IL13 |
8件: Asthma, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, IL-17 signaling pathway, Inflammatory bowel disease (IBD), JAK-STAT signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation |
1件: 85 |
141 |
Letairis |
Ambrisentan |
D07077 |
1件: EDNRA |
7件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Pathways in cancer, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
1件: 85 |
142 |
Letairis 10 mg |
Ambrisentan |
D07077 |
1件: EDNRA |
7件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Pathways in cancer, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
1件: 85 |
143 |
Letairis 5 mg |
Ambrisentan |
D07077 |
1件: EDNRA |
7件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Pathways in cancer, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
1件: 85 |
144 |
Losartan |
Losartan |
D00357, D08146 |
1件: AGTR1 |
14件: AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
18件: 13, 17, 19, 46, 58, 66, 67, 85, 96, 97, 98, 113, 164, 167, 179, 215, 222, 299 |
145 |
Low dose bibf 1120 twice daily |
- |
- |
- |
- |
1件: 85 |
146 |
Low dose bibf1120 once daily |
- |
- |
- |
- |
1件: 85 |
147 |
Lung stem cells |
- |
- |
- |
- |
1件: 85 |
148 |
Macitentan |
Macitentan |
D10135 |
2件: EDNRA, EDNRB |
9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
5件: 51, 85, 86, 88, 210 |
149 |
Medical air |
Medical air |
- |
- |
- |
3件: 85, 86, 193 |
150 |
Medical air (sham o2) |
Medical air |
- |
- |
- |
1件: 85 |
151 |
Mg-s-2525 |
- |
- |
- |
- |
1件: 85 |
152 |
Minocycline |
Minocycline |
D00850, D05045 |
- |
- |
13件: 2, 6, 8, 13, 46, 85, 90, 94, 162, 201, 206, 280, 299 |
153 |
Monitor |
Methamidophos |
- |
- |
- |
12件: 2, 11, 13, 19, 46, 49, 58, 70, 85, 98, 298, 300 |
154 |
Montelukast |
Montelukast |
D00529, D08229 |
1件: CYSLTR1 |
2件: Calcium signaling pathway, Neuroactive ligand-receptor interaction |
5件: 13, 46, 85, 98, 228 |
155 |
Moxifloxacin |
Moxifloxacin |
D00874, D08237 |
- |
- |
8件: 2, 6, 46, 49, 85, 86, 240, 299 |
156 |
Mycophenolate |
Mycophenolic acid |
D05096 |
2件: IMPDH1, IMPDH2 |
3件: Drug metabolism - other enzymes, Metabolic pathways, Purine metabolism |
33件: 2, 11, 13, 14, 19, 20, 28, 35, 36, 42, 43, 45, 49, 51, 53, 60, 62, 65, 66, 84, 85, 95, 96, 162, 164, 222, 224, 226, 234, 283, 284, 285, 300 |
157 |
Mycophenolate mofetil |
Mycophenolate mofetil |
D00752, D05094, D05095 |
2件: IMPDH1, IMPDH2 |
3件: Drug metabolism - other enzymes, Metabolic pathways, Purine metabolism |
32件: 2, 11, 13, 14, 19, 20, 28, 35, 36, 42, 43, 45, 49, 51, 53, 60, 62, 65, 66, 85, 95, 96, 162, 164, 222, 224, 226, 234, 283, 284, 285, 300 |
158 |
N-acetyl cysteine |
L-cysteine |
D00026, D02326 |
- |
- |
5件: 13, 19, 85, 88, 296 |
159 |
N-acetylcysteine |
Acetylcysteine |
D00221 |
- |
- |
10件: 6, 13, 19, 20, 49, 58, 85, 111, 164, 299 |
160 |
N-acetylcysteine, (nac) |
Acetylcysteine |
D00221 |
- |
- |
1件: 85 |
161 |
Nalbuphine |
Nalbuphine |
D00843, D08246 |
3件: OPRD1, OPRK1, OPRM1 |
5件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway |
1件: 85 |
162 |
Nalbuphine er |
Nalbuphine |
D00843, D08246 |
3件: OPRD1, OPRK1, OPRM1 |
5件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway |
1件: 85 |
163 |
Nandrolone |
Nandrolone |
D08250 |
1件: AR |
3件: Oocyte meiosis, Pathways in cancer, Prostate cancer |
2件: 60, 85 |
164 |
Nandrolone decanoate |
Nandrolone decanoate |
D00955 |
1件: AR |
3件: Oocyte meiosis, Pathways in cancer, Prostate cancer |
2件: 60, 85 |
165 |
Nd-l02-s0201 |
- |
- |
- |
- |
1件: 85 |
166 |
Nintedanib |
Nintedanib |
D10481 |
8件: FGFR1, FGFR2, FGFR3, FLT1, FLT4, KDR, PDGFRA, PDGFRB |
34件: Adherens junction, Bladder cancer, Breast cancer, Calcium signaling pathway, Central carbon metabolism in cancer, Choline metabolism in cancer, EGFR tyrosine kinase inhibitor resistance, Endocytosis, Fluid shear stress and atherosclerosis, Focal adhesion, Gap junction, Gastric cancer, Glioma, HIF-1 signaling pathway, Human cytomegalovirus infection, Human papillomavirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanoma, MicroRNAs in cancer, PI3K-Akt signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Rheumatoid arthritis, Signaling pathways regulating pluripotency of stem cells, Thermogenesis, Transcriptional misregulation in cancer, VEGF signaling pathway |
4件: 51, 85, 89, 228 |
167 |
Nitric oxide |
Nitric oxide |
D00074 |
- |
- |
7件: 46, 85, 86, 98, 251, 294, 299 |
168 |
Octreotide |
Octreotide |
D00442, D06495 |
1件: SSTR2 |
4件: Gastric acid secretion, Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
7件: 67, 75, 84, 85, 89, 193, 227 |
169 |
Ofev |
Nintedanib |
D10481 |
8件: FGFR1, FGFR2, FGFR3, FLT1, FLT4, KDR, PDGFRA, PDGFRB |
34件: Adherens junction, Bladder cancer, Breast cancer, Calcium signaling pathway, Central carbon metabolism in cancer, Choline metabolism in cancer, EGFR tyrosine kinase inhibitor resistance, Endocytosis, Fluid shear stress and atherosclerosis, Focal adhesion, Gap junction, Gastric cancer, Glioma, HIF-1 signaling pathway, Human cytomegalovirus infection, Human papillomavirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanoma, MicroRNAs in cancer, PI3K-Akt signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Rheumatoid arthritis, Signaling pathways regulating pluripotency of stem cells, Thermogenesis, Transcriptional misregulation in cancer, VEGF signaling pathway |
4件: 51, 85, 89, 228 |
170 |
Ofev 100 mg capsule |
Nintedanib |
D10481 |
8件: FGFR1, FGFR2, FGFR3, FLT1, FLT4, KDR, PDGFRA, PDGFRB |
34件: Adherens junction, Bladder cancer, Breast cancer, Calcium signaling pathway, Central carbon metabolism in cancer, Choline metabolism in cancer, EGFR tyrosine kinase inhibitor resistance, Endocytosis, Fluid shear stress and atherosclerosis, Focal adhesion, Gap junction, Gastric cancer, Glioma, HIF-1 signaling pathway, Human cytomegalovirus infection, Human papillomavirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanoma, MicroRNAs in cancer, PI3K-Akt signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Rheumatoid arthritis, Signaling pathways regulating pluripotency of stem cells, Thermogenesis, Transcriptional misregulation in cancer, VEGF signaling pathway |
1件: 85 |
171 |
Ofev 150 mg capsule |
Nintedanib |
D10481 |
8件: FGFR1, FGFR2, FGFR3, FLT1, FLT4, KDR, PDGFRA, PDGFRB |
34件: Adherens junction, Bladder cancer, Breast cancer, Calcium signaling pathway, Central carbon metabolism in cancer, Choline metabolism in cancer, EGFR tyrosine kinase inhibitor resistance, Endocytosis, Fluid shear stress and atherosclerosis, Focal adhesion, Gap junction, Gastric cancer, Glioma, HIF-1 signaling pathway, Human cytomegalovirus infection, Human papillomavirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanoma, MicroRNAs in cancer, PI3K-Akt signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Rheumatoid arthritis, Signaling pathways regulating pluripotency of stem cells, Thermogenesis, Transcriptional misregulation in cancer, VEGF signaling pathway |
1件: 85 |
172 |
Omeprazole |
Omeprazole |
D00455, D01207, D05259, D05261 |
2件: ATP4A, ATP4B |
4件: Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation |
15件: 6, 8, 13, 46, 51, 85, 96, 97, 98, 225, 271, 282, 294, 298, 299 |
173 |
Omeprazole (uk licensed generic product) |
Omeprazole |
D00455, D01207, D05259, D05261 |
2件: ATP4A, ATP4B |
4件: Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation |
1件: 85 |
174 |
Oxygen |
Oxygen |
D00003 |
- |
- |
14件: 46, 49, 70, 84, 85, 86, 88, 90, 96, 97, 193, 226, 299, 330 |
175 |
Oxygen 40 % |
Oxygen |
D00003 |
- |
- |
1件: 85 |
176 |
Pa101 |
- |
- |
- |
- |
1件: 85 |
177 |
Paclitaxel |
Paclitaxel |
D00491, D05333 |
9件: TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 |
3件: Gap junction, Pathogenic Escherichia coli infection, Phagosome |
2件: 46, 85 |
178 |
Pamrevlumab |
Pamrevlumab |
D10969 |
1件: CCN2 |
2件: Apelin signaling pathway, Hippo signaling pathway |
2件: 85, 113 |
179 |
Pbi4050 |
- |
- |
- |
- |
2件: 85, 299 |
180 |
Pir, s-7701 |
- |
- |
- |
- |
1件: 85 |
181 |
Pirfenidone |
Pirfenidone |
D01583 |
6件: CCL2, IL10, IL1A, IL1B, IL6, TNF |
80件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, Autoimmune thyroid disease, C-type lectin receptor signaling pathway, Cellular senescence, Chagas disease (American trypanosomiasis), Chemokine signaling pathway, Cytokine-cytokine receptor interaction, Cytosolic DNA-sensing pathway, Dilated cardiomyopathy (DCM), EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, FoxO signaling pathway, Graft-versus-host disease, HIF-1 signaling pathway, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Inflammatory mediator regulation of TRP channels, Influenza A, Insulin resistance, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, Measles, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Pertussis, Prion diseases, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Staphylococcus aureus infection, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Transcriptional misregulation in cancer, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
10件: 34, 46, 50, 51, 58, 84, 85, 164, 222, 228 |
182 |
Pirfenidone and nintedanib |
Pirfenidone |
D01583 |
6件: CCL2, IL10, IL1A, IL1B, IL6, TNF |
80件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, Autoimmune thyroid disease, C-type lectin receptor signaling pathway, Cellular senescence, Chagas disease (American trypanosomiasis), Chemokine signaling pathway, Cytokine-cytokine receptor interaction, Cytosolic DNA-sensing pathway, Dilated cardiomyopathy (DCM), EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, FoxO signaling pathway, Graft-versus-host disease, HIF-1 signaling pathway, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Inflammatory mediator regulation of TRP channels, Influenza A, Insulin resistance, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, Measles, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Pertussis, Prion diseases, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Staphylococcus aureus infection, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Transcriptional misregulation in cancer, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
1件: 85 |
183 |
Pirfenidone or nintedanib |
Pirfenidone |
D01583 |
6件: CCL2, IL10, IL1A, IL1B, IL6, TNF |
80件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, Autoimmune thyroid disease, C-type lectin receptor signaling pathway, Cellular senescence, Chagas disease (American trypanosomiasis), Chemokine signaling pathway, Cytokine-cytokine receptor interaction, Cytosolic DNA-sensing pathway, Dilated cardiomyopathy (DCM), EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, FoxO signaling pathway, Graft-versus-host disease, HIF-1 signaling pathway, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Inflammatory mediator regulation of TRP channels, Influenza A, Insulin resistance, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, Measles, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Pertussis, Prion diseases, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Staphylococcus aureus infection, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Transcriptional misregulation in cancer, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
1件: 85 |
184 |
Pirfenidoneone |
- |
- |
- |
- |
1件: 85 |
185 |
Placebo |
- |
- |
- |
- |
20件: 3, 6, 13, 14, 40, 46, 49, 50, 51, 66, 67, 79, 85, 86, 88, 96, 97, 144, 149, 226 |
186 |
Pln-74809 |
- |
- |
- |
- |
1件: 85 |
187 |
Pomalidomide |
Pomalidomide |
D08976 |
2件: IL6, TNF |
76件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Cellular senescence, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Cytosolic DNA-sensing pathway, Dilated cardiomyopathy (DCM), EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, FoxO signaling pathway, Graft-versus-host disease, HIF-1 signaling pathway, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, Measles, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Pertussis, Prion diseases, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Transcriptional misregulation in cancer, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
6件: 28, 34, 51, 85, 227, 331 |
188 |
Pomalidomide (cc-4047 |
Pomalidomide |
D08976 |
2件: IL6, TNF |
76件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Cellular senescence, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Cytosolic DNA-sensing pathway, Dilated cardiomyopathy (DCM), EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, FoxO signaling pathway, Graft-versus-host disease, HIF-1 signaling pathway, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, Measles, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Pertussis, Prion diseases, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Transcriptional misregulation in cancer, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
1件: 85 |
189 |
Prednisolone |
Prednisolone |
D00472, D00980, D00981, D00982, D01239, D01998, D02156, D03301 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
38件: 11, 13, 25, 26, 35, 38, 39, 41, 43, 44, 45, 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 113, 145, 162, 222, 269, 271, 296, 299, 300 |
190 |
Prednisone |
Prednisone |
D00473 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
43件: 2, 11, 13, 14, 26, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 61, 63, 64, 65, 66, 81, 84, 85, 86, 95, 96, 97, 113, 162, 164, 222, 224, 228, 251, 283, 284, 285, 288, 299, 300, 331 |
191 |
Privigen 100mg/ml |
- |
- |
- |
- |
1件: 85 |
192 |
Prm-151 |
- |
- |
- |
- |
1件: 85 |
193 |
Pzn 8881655(rochepharma ag) |
- |
- |
- |
- |
1件: 85 |
194 |
Qax576 |
- |
- |
- |
- |
4件: 51, 85, 96, 98 |
195 |
Quercetin |
Quercetin |
- |
- |
- |
5件: 84, 85, 192, 285, 299 |
196 |
Remicade |
Infliximab |
D02598 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
8件: 46, 49, 56, 84, 85, 96, 97, 271 |
197 |
Revatio |
Sildenafil |
D02229, D08514 |
1件: PDE5A |
3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway |
2件: 85, 86 |
198 |
Revatio 20 mg |
Sildenafil |
D02229, D08514 |
1件: PDE5A |
3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway |
1件: 85 |
199 |
Rituximab |
Rituximab |
D02994 |
1件: MS4A1 |
1件: Hematopoietic cell lineage |
42件: 11, 13, 14, 17, 35, 36, 43, 44, 45, 46, 49, 50, 51, 52, 53, 56, 60, 61, 63, 64, 65, 66, 83, 84, 85, 86, 93, 94, 96, 97, 162, 222, 223, 229, 256, 271, 283, 284, 285, 288, 300, 331 |
200 |
Rixathon 500 mg |
- |
- |
- |
- |
1件: 85 |
201 |
Ro 47-0203 |
Bosentan |
D01227, D07538 |
2件: EDNRA, EDNRB |
9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
4件: 51, 85, 86, 88 |
202 |
Ro0220912 |
- |
- |
- |
- |
1件: 85 |
203 |
Ro0280296 |
- |
- |
- |
- |
1件: 85 |
204 |
Ro5490255 |
- |
- |
- |
- |
1件: 85 |
205 |
Rvt-1601 |
- |
- |
- |
- |
1件: 85 |
206 |
Salbutamol |
Salbutamol |
D02147 |
1件: ADRB2 |
8件: Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway |
8件: 3, 11, 49, 85, 86, 228, 256, 299 |
207 |
Sar156597 |
- |
- |
- |
- |
2件: 51, 85 |
208 |
Septrin |
- |
- |
- |
- |
1件: 85 |
209 |
Sildenafil |
Sildenafil |
D02229, D08514 |
1件: PDE5A |
3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway |
15件: 6, 46, 50, 51, 85, 86, 113, 210, 211, 212, 225, 226, 278, 294, 299 |
210 |
Sildenafil (50 mg) |
Sildenafil |
D02229, D08514 |
1件: PDE5A |
3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway |
1件: 85 |
211 |
Sildenafil and losartan |
Sildenafil |
D02229, D08514 |
1件: PDE5A |
3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway |
1件: 85 |
212 |
Sildenafil citrate |
Sildenafil |
D02229, D08514 |
1件: PDE5A |
3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway |
4件: 51, 85, 86, 225 |
213 |
Simtuzumab |
Simtuzumab |
- |
- |
- |
2件: 85, 94 |
214 |
Sirolimus |
Sirolimus |
D00753 |
1件: MTOR |
43件: AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Choline metabolism in cancer, Colorectal cancer, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway |
30件: 13, 17, 34, 35, 36, 46, 51, 60, 62, 63, 65, 66, 67, 85, 89, 96, 98, 137, 157, 158, 192, 222, 277, 278, 279, 280, 281, 283, 285, 331 |
215 |
Sivelestat |
Sivelestat |
D03788 |
1件: ELANE |
2件: Systemic lupus erythematosus, Transcriptional misregulation in cancer |
3件: 13, 85, 96 |
216 |
Sm04646 |
- |
- |
- |
- |
1件: 85 |
217 |
Standard of care |
- |
- |
- |
- |
8件: 6, 13, 14, 49, 51, 64, 79, 85 |
218 |
Standard steroid treatment |
- |
- |
- |
- |
1件: 85 |
219 |
Sub-study: fg-3019 |
- |
- |
- |
- |
1件: 85 |
220 |
Sub-study: nintedanib |
Nintedanib |
D10481 |
8件: FGFR1, FGFR2, FGFR3, FLT1, FLT4, KDR, PDGFRA, PDGFRB |
34件: Adherens junction, Bladder cancer, Breast cancer, Calcium signaling pathway, Central carbon metabolism in cancer, Choline metabolism in cancer, EGFR tyrosine kinase inhibitor resistance, Endocytosis, Fluid shear stress and atherosclerosis, Focal adhesion, Gap junction, Gastric cancer, Glioma, HIF-1 signaling pathway, Human cytomegalovirus infection, Human papillomavirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanoma, MicroRNAs in cancer, PI3K-Akt signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Rheumatoid arthritis, Signaling pathways regulating pluripotency of stem cells, Thermogenesis, Transcriptional misregulation in cancer, VEGF signaling pathway |
1件: 85 |
221 |
Sub-study: pirfenidone |
Pirfenidone |
D01583 |
6件: CCL2, IL10, IL1A, IL1B, IL6, TNF |
80件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, Autoimmune thyroid disease, C-type lectin receptor signaling pathway, Cellular senescence, Chagas disease (American trypanosomiasis), Chemokine signaling pathway, Cytokine-cytokine receptor interaction, Cytosolic DNA-sensing pathway, Dilated cardiomyopathy (DCM), EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, FoxO signaling pathway, Graft-versus-host disease, HIF-1 signaling pathway, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Inflammatory mediator regulation of TRP channels, Influenza A, Insulin resistance, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, Measles, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Pertussis, Prion diseases, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Staphylococcus aureus infection, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Transcriptional misregulation in cancer, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
1件: 85 |
222 |
Sulfamethoxazole |
Sulfamethoxazole |
D00447 |
- |
- |
4件: 44, 49, 85, 299 |
223 |
Symbicort |
Formoterol |
D01373, D05277, D07990 |
1件: ADRB2 |
8件: Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway |
2件: 85, 228 |
224 |
Tacrolimus |
Tacrolimus |
D00107, D08556 |
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 |
30件: Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway |
29件: 2, 11, 13, 36, 46, 49, 50, 51, 53, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 228, 283, 284, 299 |
225 |
Td139 |
Td139 |
- |
- |
- |
1件: 85 |
226 |
Tetrathiomolybdate |
Tetrathiomolybdate |
- |
- |
- |
3件: 85, 93, 171 |
227 |
Thalidomide |
Thalidomide |
D00754 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
18件: 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 |
228 |
Thalidomide pharmion |
Thalidomide |
D00754 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
3件: 85, 96, 97 |
229 |
The standard steroid treatment, plasma exchange and rituximab |
Rituximab |
D02994 |
1件: MS4A1 |
1件: Hematopoietic cell lineage |
1件: 85 |
230 |
Thiotepa |
Thiotepa |
D00583 |
- |
- |
11件: 13, 19, 20, 28, 51, 60, 65, 85, 96, 164, 284 |
231 |
Thrombomodulin alfa |
Thrombomodulin alfa |
D06410 |
1件: F2 |
7件: Complement and coagulation cascades, Neuroactive ligand-receptor interaction, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Platelet activation, Regulation of actin cytoskeleton |
1件: 85 |
232 |
Tiotropium |
Tiotropium |
- |
- |
- |
3件: 55, 85, 299 |
233 |
Tipelukast |
Tipelukast |
D06659 |
1件: CYSLTR1 |
2件: Calcium signaling pathway, Neuroactive ligand-receptor interaction |
1件: 85 |
234 |
Tracleer |
Bosentan |
D01227, D07538 |
2件: EDNRA, EDNRB |
9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
8件: 13, 51, 84, 85, 86, 88, 210, 211 |
235 |
Tralokinumab |
Tralokinumab |
D09979 |
1件: IL13 |
8件: Asthma, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, IL-17 signaling pathway, Inflammatory bowel disease (IBD), JAK-STAT signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation |
2件: 85, 97 |
236 |
Tralokinumab cohort 1 |
Tralokinumab |
D09979 |
1件: IL13 |
8件: Asthma, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, IL-17 signaling pathway, Inflammatory bowel disease (IBD), JAK-STAT signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation |
1件: 85 |
237 |
Tralokinumab cohort 2 |
Tralokinumab |
D09979 |
1件: IL13 |
8件: Asthma, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, IL-17 signaling pathway, Inflammatory bowel disease (IBD), JAK-STAT signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation |
1件: 85 |
238 |
Tralokinumab is a human recombinant monoclonal antibody (mab) of the subclass that specifically binds human il-13, blocking interactions with the il-13 receptor |
Tralokinumab |
D09979 |
1件: IL13 |
8件: Asthma, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, IL-17 signaling pathway, Inflammatory bowel disease (IBD), JAK-STAT signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation |
1件: 85 |
239 |
Treatment as usual (tau) |
- |
- |
- |
- |
1件: 85 |
240 |
Treprostinil |
Treprostinil |
D06213 |
1件: PTGIR |
3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
5件: 51, 84, 85, 86, 88 |
241 |
Treprostinil sodium for inhalation |
Treprostinil |
D06213 |
1件: PTGIR |
3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
1件: 85 |
242 |
Trimethoprim |
Trimethoprim |
D00145, D06236 |
- |
- |
6件: 36, 44, 49, 60, 85, 299 |
243 |
Trk-250 |
- |
- |
- |
- |
1件: 85 |
244 |
Valganciclovir |
Valganciclovir |
D02495 |
- |
- |
6件: 28, 60, 85, 97, 299, 331 |
245 |
Vasoactive intestinal peptide |
- |
- |
- |
- |
1件: 85 |
246 |
Vay736 |
- |
- |
- |
- |
7件: 13, 35, 46, 49, 53, 85, 95 |
247 |
Vismodegib |
Vismodegib |
D09992 |
1件: SMO |
5件: Axon guidance, Basal cell carcinoma, Hedgehog signaling pathway, Pathways in cancer, Proteoglycans in cancer |
1件: 85 |
248 |
Vrp700 |
- |
- |
- |
- |
1件: 85 |
249 |
Warfarin |
Warfarin |
D00564, D01280, D08682 |
2件: NQO1, VKORC1 |
5件: Fluid shear stress and atherosclerosis, Hepatocellular carcinoma, Metabolic pathways, Pathways in cancer, Ubiquinone and other terpenoid-quinone biosynthesis |
10件: 6, 8, 13, 19, 46, 49, 66, 85, 88, 96 |
250 |
Xenon |
Xenon |
D01901, D06339 |
- |
- |
5件: 22, 85, 228, 231, 299 |
251 |
Zileuton |
Zileuton |
D00414 |
1件: ALOX5 |
6件: Arachidonic acid metabolism, Fc epsilon RI signaling pathway, Metabolic pathways, Ovarian steroidogenesis, Serotonergic synapse, Toxoplasmosis |
3件: 85, 160, 164 |
252 |
Zl-2102 |
- |
- |
- |
- |
1件: 85 |
253 |
Zsp1603 12.5 mg |
- |
- |
- |
- |
1件: 85 |
254 |
Zsp1603 25 mg |
- |
- |
- |
- |
1件: 85 |
255 |
Zsp1603 50 mg |
- |
- |
- |
- |
1件: 85 |
256 |
Zsp1603 7.5 mg |
- |
- |
- |
- |
1件: 85 |